---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-301791"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:48:13.269022+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Galera receives Nasdaq delisting notice for failing to meet $50M MVLS; plans appeal

## Summary
- Nasdaq notified Galera on Dec 6, 2022 of failure to regain compliance with $50M MVLS requirement by Dec 5 deadline.
- Trading suspension and delisting from Nasdaq Global Market scheduled for Dec 15 unless hearing requested by Dec 13.
- Company will request a hearing to appeal; request will stay suspension pending Panel decision.
- May seek transfer to Nasdaq Capital Market if Global Market listing is not continued.

## SEC filing metadata
- accession: 0001193125-22-301791
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312522301791/0001193125-22-301791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312522301791/d414316d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-301791
- JSON: https://secwatch.observer/filing/0001193125-22-301791.json
- Plain text: https://secwatch.observer/filing/0001193125-22-301791.txt

## Key facts
- Listing & Compliance Notices
  Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A)
  source text: December 6, 2022, Galera Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company has not regained compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”), and that, unless the Company requests a hearing before a Nasdaq Hearings Panel (“Panel”) to appeal Nasdaq’s delisting determination by 4:00 p.m. Eastern Time on December 13
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312522301791/0001193125-22-301791-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.